Par Pharmaceutical Companies Inc. (NYSE:PRX) announced that it entered into a definitive agreement to acquire Anchen Pharmaceuticals, a privately-held specialty pharmaceutical company focused on developing and commercializing extended release and niche generic products, for $410 million in cash. The transaction is expected to be immediately accretive to non-GAAP earnings in 2011.
Read more at : http://stock-pr.com/?p=19617
(PRX, DLR, ONB, CRWE) Featured Stock by Stock-PR.com
August 27th, 2011 at 10:36 am